posted June 23, 2000 01:19 AM            

Here is some info from Medline:
"In studies conducted with the immediate-release formulation of bupropion, a weight loss of greater than 5 pounds occurred in 28% of bupropion HCl patients. This incidence is approximately double that seen in comparable patients treated with tricyclics or placebo. Furthermore, 35% of patients receiving tricyclic antidepressants gained weight, compared to 9% of patients treated with the immediate-release formulation of bupropion. If weight loss is a major presenting sign of a patient's depressive illness, the anorectic and/or weight-reducing potential of bupropion HCl sustained release tablets should be considered."

------------------

Yours in sport,

George

George Spellwin
Research Director

posted June 23, 2000 01:27 PM            

J Clin Psychiatry 1998;59 Suppl 4:32-6
Related Articles, Books, LinkOut

Bupropion sustained release: side effect profile.

Settle EC Jr

Department of Psychiatry, West Virginia University, Charleston, USA.

Bupropion IR (immediate release) has been on the market since 1988 and is an effective and usually well-tolerated
antidepressant. In late 1996, a new sustained-release formulation, bupropion SR, was approved and is now available.
Compared with the IR formulation, the SR formulation demonstrates similar efficacy and has been found to have similar, but to
some degree fewer, side effects. Its efficacy is similar to that of other newer antidepressants. Side effects of bupropion SR are
limited and are not dissimilar to those of the serotonergic antidepressants; however, bupropion SR produces neither substantial
sexual side effects nor drug interactions. Study data demonstrate that seizure incidence, which is a concern with high-dose IR,
is substantially lower with the new SR formulation.

Publication Types:
Review
Review, tutorial

PMID: 9554319, UI: 98212981

----------------------
Clin Ther 1999 Mar;21(3):454-63
Related Articles, Books, LinkOut

Safety profile of sustained-release bupropion in depression: results of three clinical trials.

Settle EC, Stahl SM, Batey SR, Johnston JA, Ascher JA

University of California at San Diego, California, USA.

This series of studies was undertaken to assess the safety profile of sustained-release (SR) bupropion in the treatment of
depressed outpatients. Adults with a diagnosis of major depression were evaluated in 1 of 3 multicenter, randomized,
double-masked, parallel-group, placebo-controlled trials conducted in private-practice psychiatric outpatient clinics. Following
a 1-week, single-masked, placebo lead-in period, patients received bupropion SR for 8 weeks (study 1: 150 or 300 mg/d;
study 2: 100, 200, 300, or 400 mg/d; study 3: 50 to 150 or 100 to 300 mg/d). Safety assessments included monitoring
adverse events, patient discontinuation rates, changes in weight, vital signs, and clinical laboratory test results. Across studies,
the most frequently reported adverse events were headache, dry mouth, and nausea. The incidence of adverse events was
similar (< or =5% difference) between the bupropion SR and placebo groups, with the exception of dry mouth (bupropion SR,
16%; placebo, 7%). Dry mouth, nausea, and insomnia occurred significantly more often in bupropion SR-treated patients than
in patients who received placebo (P<0.05). Nearly all (94% to 99%) adverse events reported in these studies were mild or
moderate. Less than 10% of patients in either group discontinued treatment prematurely because of adverse events, and no
deaths or serious drug-related adverse events were reported. Sexual dysfunction was reported as an adverse event by <1% of
patients in either group. Bupropion SR was associated with dose-related weight loss in all 3 studies. No consistent patterns of
change were observed in vital signs or in the results of clinical laboratory tests. Data from these 3 clinical trials demonstrate the
favorable safety profile of bupropion SR in the treatment of depressed outpatients.

Publication Types:
Clinical trial
Multicenter study
Randomized controlled trial

PMID: 10321415, UI: 99253332

[This message has been edited by Puc (edited June 23, 2000).]

posted June 23, 2000 02:20 PM            

I have just been impressed with the amount of fat my client has lost.

------------------

Yours in sport,

George

George Spellwin
Research Director

posted June 23, 2000 02:36 PM            

my ass has been on medline since I read this.

I think I like it.

posted June 24, 2000 10:51 AM         

Luo S, Luo J, Cincotta AH.

Association of the antidiabetic effects of bromocriptine with a shift in the daily rhythm of monoamine metabolism within the suprachiasmatic nuclei of the Syrian hamster.
Chronobiol Int. 2000 Mar;17(2):155-72.

Kraszewski KZ, Cincotta AH.

Increased responsiveness of ventromedial hypothalamic neurons to norepinephrine in obese versus lean mice: relation to the metabolic syndrome.
Int J Mol Med. 2000 Apr;5(4):349-55.

Zhang Y, Scislowski PW, Prevelige R, Phaneuf S, Cincotta AH.

Bromocriptine/SKF38393 treatment ameliorates dyslipidemia in ob/ob mice.
Metabolism. 1999 Aug;48(8):1033-40.

Scislowski PW, Tozzo E, Zhang Y, Phaneuf S, Prevelige R, Cincotta AH.

Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists.
Int J Obes Relat Metab Disord. 1999 Apr;23(4):425-31.

Luo S, Liang Y, Cincotta AH.

Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters.
Neuroendocrinology. 1999 Mar;69(3):160-6.

Liang Y, Lubkin M, Sheng H, Scislowski PW, Cincotta AH.

Dopamine agonist treatment ameliorates hyperglycemia, hyperlipidemia, and the elevated basal insulin release from islets of ob/ob mice.
Biochim Biophys Acta. 1998 Oct 21;1405(1-3):1-13.

Luo S, Meier AH, Cincotta AH.

Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters.
Neuroendocrinology. 1998 Jul;68(1):1-10.

Greenman Y, Tordjman K, Stern N.

Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels.
Clin Endocrinol (Oxf). 1998 May;48(5):547-53.

Kamath V, Jones CN, Yip JC, Varasteh BB, Cincotta AH, Reaven GM, Chen YD.

Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women.
Diabetes Care. 1997 Nov;20(11):1697-701.

Cincotta AH, Tozzo E, Scislowski PW.

Bromocriptine/SKF38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob/ob) mice.
Life Sci. 1997;61(10):951-6.

Kreft B, Peters A, Kerner W.

[The therapy of a macroprolactinoma with the intramuscular application of a long-acting bromocriptine preparation].
Dtsch Med Wochenschr. 1996 Jul 5;121(27):865-8. Review. German.

Cincotta AH, Meier AH.

Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects.
Diabetes Care. 1996 Jun;19(6):667-70.

Maccario M, Grottoli S, Procopio M, Oleandri SE, Barberis A, Ciccarelli E, Camanni F, Ghigo E.

Effect of bromocriptine on insulin, growth hormone and prolactin responses to arginine in obesity.
J Endocrinol Invest. 1996 Apr;19(4):219-23.

Cincotta AH, Meier AH.

Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricetus auratus).
Metabolism. 1995 Oct;44(10):1349-55.

Roush W.

Can "resetting" hormonal rhythms treat illness?
Science. 1995 Sep 1;269(5228):1220-1. No abstract available.

Meier AH, Cincotta AH, Lovell WC.

Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics.
Experientia. 1992 Mar 15;48(3):248-53.

Cincotta AH, Schiller BC, Meier AH.

Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratus.
Metabolism. 1991 Jun;40(6):639-44.